Associations of methylenetetrahydrofolate reductase gene (MTHFR) rs1801131 and rs1801133 polymorphisms with susceptibility to vitiligo: A meta-analysis
- PMID: 33219596
- DOI: 10.1111/jocd.13857
Associations of methylenetetrahydrofolate reductase gene (MTHFR) rs1801131 and rs1801133 polymorphisms with susceptibility to vitiligo: A meta-analysis
Abstract
Background: Vitiligo is a common pigmentary skin disorder, and genetic factors were acknowledged to be greatly associated with the pathogenesis of this disease. Recently, increasing studies investigated the associations of methylenetetrahydrofolate reductase (MTHFR) rs1801131 and rs1801133 polymorphisms with risks of vitiligo, but the results still remained controversial.
Aim: The current meta-analysis was conducted to further evaluate the association of MTHFR polymorphisms with risk of vitiligo.
Methods: Eligible studies were searched in PubMed, EMBASE, Cochrane library, Chinese National Knowledge Infrastructure (CNKI), Technology of Chongqing (VIP), and Wan Fang Database until October 2020. All analyses were carried out using the Review Manager 5.3 software.
Results: A total of 6 studies that involved MTHFR rs1801131 and/or rs1801133 polymorphism were finally included, which enrolled 3599 participants. Our results showed that no correlations were found between MTHFR rs1801131, rs1801133 polymorphisms and vitiligo risks in overall group. However, subgroup analysis revealed that rs1801131 polymorphism was significantly associated with increased vitiligo risk in the allelic (C vs A: OR = 1.15, 95% CI = 1.02-1.29, P = .02) and homozygous models (CC vs AA: OR = 1.48, 95% CI = 1.10-2.01, P = .01) in Asian population and that the rs1801133 polymorphism was significantly associated with decreased vitiligo risk in the allelic model (T vs C: OR = 0.82, 95% CI = 0.74-0.92, P = .0005) also in Asian population.
Conclusions: This meta-analysis confirmed the associations of MTHFR rs1801131 and rs1801133 polymorphisms with vitiligo risks and provided comprehensive insight into the pathogenesis of vitiligo.
Keywords: MTHFR; meta-analysis; polymorphism; susceptibility; vitiligo.
© 2020 Wiley Periodicals LLC.
Similar articles
-
Genetic polymorphisms in the methylenetetrahydrofolate reductase gene (MTHFR) and risk of vitiligo in Han Chinese populations: a genotype-phenotype correlation study.Br J Dermatol. 2014 May;170(5):1092-9. doi: 10.1111/bjd.12845. Br J Dermatol. 2014. PMID: 24472005
-
Methylenetetrahydrofolate Reductase Gene rs1801133 and rs1801131 Polymorphisms and Essential Hypertension Risk: A Comprehensive Analysis.Cardiovasc Ther. 2022 Feb 22;2022:2144443. doi: 10.1155/2022/2144443. eCollection 2022. Cardiovasc Ther. 2022. PMID: 35284002 Free PMC article.
-
Methylenetetrahydrofolate reductase polymorphisms and colorectal cancer prognosis: A meta-analysis.J Gene Med. 2019 Sep;21(9):e3114. doi: 10.1002/jgm.3114. Epub 2019 Aug 6. J Gene Med. 2019. PMID: 31330573 Free PMC article. Review.
-
Associations between methylenetetrahydrofolate reductase polymorphisms and hepatocellular carcinoma risk: An update meta-analysis and trial sequential analysis.Medicine (Baltimore). 2021 Oct 15;100(41):e27527. doi: 10.1097/MD.0000000000027527. Medicine (Baltimore). 2021. PMID: 34731145 Free PMC article.
-
Methylenetetrahydrofolate reductase C677T (Ala>Val, rs1801133 C>T) polymorphism decreases the susceptibility of hepatocellular carcinoma: a meta-analysis involving 12,628 subjects.Biosci Rep. 2020 Feb 28;40(2):BSR20194229. doi: 10.1042/BSR20194229. Biosci Rep. 2020. PMID: 32010931 Free PMC article. Review.
Cited by
-
Association between Psoriasis and MTHFR polymorphisms: a systematic review and meta-analysis.Arch Dermatol Res. 2024 May 21;316(5):184. doi: 10.1007/s00403-024-02905-5. Arch Dermatol Res. 2024. PMID: 38771513
-
Association of rs4711998 of IL-17A, rs2275913 of IL-17A and rs763780 IL-17F gene polymorphisms with non-segmental vitiligo in a Mexican population.Arch Dermatol Res. 2023 Apr;315(3):447-454. doi: 10.1007/s00403-022-02382-8. Epub 2022 Aug 12. Arch Dermatol Res. 2023. PMID: 35960353
References
REFERENCES
-
- Boniface K, Seneschal J, Picardo M, Taieb A. Vitiligo: focus on clinical aspects, immunopathogenesis, and therapy. Clin Rev Allergy Immunol. 2018;54:52-67.
-
- Dahir AM, Thomsen SF. Comorbidities in vitiligo: comprehensive review. Int J Dermatol. 2018;57:1157-1164.
-
- Bakis-Petsoglou S, Le Guay JL, Wittal R. A randomized, double-blinded, placebo-controlled trial of pseudocatalase cream and narrowband ultraviolet B in the treatment of vitiligo. Br J Dermatol. 2009;161:910-917.
-
- Singh S, Singh U, Pandey SS. Increased level of serum Homocysteine in vitiligo. J Clin Lab Anal. 2011;25:110-112.
-
- Chen JX, Shi Q, Wang XW, et al. Genetic polymorphisms in the methylenetetrahydrofolate reductase (MTHFR) gene and risk of vitiligo in Han Chinese populations: a genotype-phenotype correlation study. Br J Dermatol. 2014;170:1092-1099.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical